What is Claimed is:

1. A medicament for preventive and/or therapeutic treatment of dermal pigmentation and/or development of skin cancer, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted),
A represents hydrogen atom or acetyl group,
E represents an aryl group which may be substituted or a heteroaryl group which may be substituted,
ring Z represents an arene which may have one or more substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above.

2. The medicament according to claim 1, wherein X is a group selected from the following connecting group α (said group may be substituted),
A is hydrogen atom or acetyl group,
E is a C_6 to C_{10} aryl group which may be substituted or a 5- to 13-membered heteroaryl group which may be substituted,
ring Z is a C_6 to C_{10} arene which may have one or more substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above, or a 5- to 13-membered heteroarene which may have one or more substituents in addition to the group represented by

formula —O—A wherein A has the same meaning as that defined above and the group represented by formula —X—E wherein each of X and E has the same meaning as that defined above.

[Connecting Group α] The following formulas:



wherein a bond at the left end binds to ring Z and a bond at the right end binds to E.

3. The medicament according to claim 1, wherein X is a group represented by the following formula (said group may be substituted):



wherein a bond at the left end binds to ring Z and a bond at the right end binds to E,

A is hydrogen atom or acetyl group,

E is a C_6 to C_{10} aryl group which may be substituted or a 5- to 13-membered heteroaryl group which may be substituted,

ring Z is a C_6 to C_{10} arene which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined above and the group represented by formula —X—E wherein each of X and E has the same meaning as that defined above, or a 5- to 13-membered heteroarene which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined above and the group

represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above.

4. The medicament according to claim 3, wherein A is hydrogen atom or acetyl group,

E is a phenyl group which may be substituted or a thiazol-2-yl group which may be substituted,

ring Z is a benzene ring which may have one or more substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above, or a naphthalene ring which may have one or more substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above.

5. The medicament according to claim 3, wherein A is hydrogen atom,

E is a 2,5-di-substituted phenyl group, a 3,5-di-substituted phenyl group, or a 4,5-di-substituted thiazol-2-yl group,

ring Z is a benzene ring which has one to three substituents in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above.

6. The medicament according to claim 3, wherein A is hydrogen atom,

E is a 2,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, a 3,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, or a 4,5-di-substituted thiazol-2-yl group,

ring Z is a benzene ring which has one to three groups selected from the following substituent group γ-1z, in addition to the group represented by formula $-O-A$ wherein A has the same meaning as that defined above and the group represented by formula $-X-E$ wherein each of X and E has the same meaning as that defined above.

[Substituent Group γ-1z] halogen atoms, nitro group, cyano group, hydroxy group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl

group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group [thiophen-2-yl group], 3-thienyl group [thiophen-3-yl group], 1-pyrrolyl group [pyrrol-1-yl group], 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group [pyridin-2-yl group], acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, {[4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group

7. The medicament according to claim 3, wherein A is hydrogen atom, E is a group selected from the group consisting of the following substituent group δ-3e, substituent group δ-5e, and substituent group δ-8e, the following partial formula (Iz-1) in the general formula (I) containing ring Z



(Iz-1)

is the following formula (Iz-2):



(Iz-2)

wherein R^z represents a group selected from the following substituent group γ-2z.

[Substituent Group δ-3e] 2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group,

2-methylsulfanyl-5-(trifluoromethyl)phenyl group,

2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group,

2-morpholino-5-(trifluoromethyl)phenyl group, 2-bromo-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group,

2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group,

2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group,

2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group,

2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group,

2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group,

2-piperidino-5-(trifluoromethyl)phenyl group,

2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group,

2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group,

2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group,

2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group

[Substituent Group δ-5e] 3,5-bis(trifluoromethyl)phenyl group,

3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group,

3-methoxy-5-(trifluoromethyl)phenyl group,

3-methoxycarbonyl-5-(trifluoromethyl)phenyl group,

3-carboxy-5-(trifluoromethyl)phenyl group

[Substituent Group δ-8e] 5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group,

5-bromo-4-(trifluoromethyl)thiazol-2-yl group,

5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-methylthiazol-2-yl group,

4,5-dimethylthiazol-2-yl group, 5-methyl-4-phenylthiazol-2-yl group,

5-(4-fluorophenyl)-4-methylthiazol-2-yl group,

4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl group, 4-ethyl-5-phenylthiazol-2-yl group,

4-isopropyl-5-phenylthiazol-2-yl group, 4-butyl-5-phenylthiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-(ethoxycarbonyl)thiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl group,

4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl group,

5-carboxymethyl-4-phenylthiazol-2-yl group, 4,5-diphenylthiazol-2-yl group, 4-benzyl-5-phenylthiazol-2-yl group, 5-phenyl-4-(trifluoromethyl)thiazol-2-yl group, 5-acetyl-4-phenylthiazol-2-yl group, 5-benzoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(pentafluorophenyl)thiazol-2-yl group, 5-methylcarbamoyl-4-phenylthiazol-2-yl group, 5-ethylcarbamoyl-4-phenylthiazol-2-yl group, 5-isopropylcarbamoyl-4-phenylthiazol-2-yl group, 5-(2-phenylethyl)carbamoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(trifluoromethyl)thiazol-2-yl group, 5-carboxy-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-(ethoxycarbonyl)methyl-4-phenylthiazol-2-yl group, 5-carboxy-4-phenylthiazol-2-yl group, 5-propylcarbamoyl-4-phenylthiazol-2-yl group

[Substituent Group γ-2z] halogen atoms, nitro group, cyano group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group, 3-thienyl group, 1-pyrrolyl group, 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group, acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, {[4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group

8. The medicament according to claim 3, wherein A is hydrogen atom, E is a group selected from the group consisting of the aforementioned substituent group δ-3e, substituent group δ-5e, and substituent group δ-8e,

the following partial formula (Iz-1) in the general formula (I) containing ring Z



(I z − 1)

is the following formula (Iz-2):



(I z − 2)

wherein R^z represents a halogen atom.

9. The medicament according to claim 3, wherein A is hydrogen atom,
E is 2,5-bis(trifluoromethyl)phenyl group, 3,5-bis(trifluoromethyl)phenyl group, or 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group,
the following partial formula (Iz-1) in the general formula (I) containing ring Z



(I z − 1)

is the following formula (Iz-2):



(I z − 2)

wherein R^z represents a halogen atom.

10. The medicament according to claim 3, wherein A is hydrogen atom,
E is 3,5-bis(trifluoromethyl)phenyl group,
the following partial formula (Iz-1) in the general formula (I) containing ring Z



(I z − 1)

is the following formula (Iz-2):



(I z − 2)

wherein R^z represents a halogen atom.

11. The medicament according to claim 3, wherein A is hydrogen atom,

E is a C_6 to C_{10} aryl group which may be substituted or a 5- to 13-membered heteroaryl group which may be substituted,

the following partial formula (Iz-1) in the general formula (I) containing ring Z



(I z − 1)

is the following formula (Iz-2):



(I z − 2)

wherein R^z represents a halogen atom.

12. The medicament according to claim 3, wherein A is hydrogen atom,

E is a 2,5-di-substituted phenyl group, a 3,5-di-substituted phenyl group, or a 4,5-di-substituted thiazol-2-yl group,

the following partial formula (Iz-1) in the general formula (I) containing ring Z



(I z − 1)

is the following formula (Iz-2):



(I z − 2)

wherein R^z represents a halogen atom.

13. The medicament according to claim 3, wherein A is hydrogen atom,
E is 3,5-bis(trifluoromethyl)phenyl group,
ring Z is a C_6 to C_{10} arene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −X−E wherein each of X and E has the same meaning as that defined above, or a 5- to 13-membered heteroarene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −X−E wherein each of X and E has the same meaning as that defined above.

14. The medicament according to claim 2, wherein the compound represented by the general formula (I) is a compound selected from the group consisting of the compounds described in the pamphlet of International Patent Publication WO03/103647 as Compound No. 1 to 555.

15. The medicament according to claim 3, wherein the compound represented by the general formula (I) is a compound selected from the group consisting of the compounds described in the pamphlet of International Patent Publication WO03/103647 as Compound No. 18 to 223 and Compound No. 322 to 555.

16. The medicament according to any one of claims 1 to 15, having inhibitory activity against transformation and/or proliferation of melanocytes caused by ultraviolet irradiation.